Combination Therapy With Recombinant Human Granulocyte Colony‐Stimulating Factor and Erythropoietin in Aplastic Anemia
作者:
Masahiro Imamura,
Masanobu Kobayashi,
Sumiko Kobayashi,
Kohki Yoshida,
Chikara Mikuni,
Yorikazu Ishikawa,
Shuzo Matsumoto,
Sumio Sakamaki,
Yoshiro Niitsu,
Yuji Hinoda,
Akira Yachi,
Tohru Kudoh,
Shunzo Chiba,
Masaharu Kasai,
Toshiaki Oka,
Akimasa Okuno,
Isao Maekawa,
Keisuke Sakurada,
Tamotsu Miyazaki,
期刊:
American Journal of Hematology
(WILEY Available online 1995)
卷期:
Volume 48,
issue 1
页码: 29-33
ISSN:0361-8609
年代: 1995
DOI:10.1002/ajh.2830480106
出版商: Wiley Subscription Services, Inc., A Wiley Company
关键词: AA;combination therapy;cytokine;EPO;G‐CSF
数据来源: WILEY
摘要:
AbstractRecombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and erythropoietin (rhEPO) were used to treat patients with aplastic anemia (AA). In terms of effects on erythrocyte recovery, the combined use of rhG‐CSF and rhEPO showed a favorable response in 6 of 14 (42.9%) patients with moderate AA following 10 weeks treatment and in 3 of 14 (21.4%) patients thereafter. However, the response was poor in patients with severe AA (3/13). A favorable response in severe AA was observed in 1 of 13 (7.7%) patients following 10 weeks treatment and in 2 of 13 (15.4%) patients thereafter. The overall effect on erythrocytes was observed in 44.4% patients. A dose of 400 μ/m2G‐CSF was sufficient to cause an increase in neutrophil count and 100 IU/kg rhEPO appeared to be sufficient to cause an increase in erythrocyte count. In 6 of 27 (22.2%) patients, a trilineage response was observed. Interestingly, a delayed and long‐lasting effect was obtained in 5 of 27 (18.5%) patients. These results suggest that rhG‐CSF can synergize with rhEPO in erythrocyte response, especially in patients with
点击下载:
PDF
(430KB)
返 回